Tofersen and Other Antisense Oligonucleotides in ALS

Overview

Journal Ther Adv Neurol Disord

Date 2025 Jan 23

PMID 39845577

Authors

Albert Ludolph

Maximilian Wiesenfarth

Affiliations

Soon will be listed here.

Abstract

The advent of antisense oligonucleotide (ASO) therapies in neurodegenerative disorders is associated with enormous hope. Nusinersen treatment was a breakthrough intervention in the recessive disease spinal muscular atrophy, and superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) seems to be the paradigm disease in dominant degenerative diseases. The results of treatment with the ASO tofersen in SOD1-ALS show that the drug has a convincing beneficial effect on ALS caused by SOD1 mutations, that preclinical studies in rodents predicted the therapeutic effect in the human disease, and that clinical efficacy is associated with a specific sequence of effects of the drug on mechanistic and degenerative biomarkers and, subsequently, functional outcomes such as weight stabilization and ALSFRS-R. Therefore, the enthusiasm seems to be justified; but this should be followed by an attempt to obtain further insights with the goal to improve this therapy. In particular, the following issues are only partially resolved: Which mechanisms are responsible for the clinical effect following the downregulation of SOD1 protein by ASOs? Is long-term downregulation of SOD1 function associated with side effects? Is there an autoimmune response caused by this and other ASO? Is prevention of SOD1-associated ALS possible?

References

Andersen P, Nilsson P, Keranen M, Forsgren L, Hagglund J, Karlsborg M . Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain. 1997; 120 ( Pt 10):1723-37. DOI: 10.1093/brain/120.10.1723. View

Ruf W, Boros M, Freischmidt A, Brenner D, Grozdanov V, de Meirelles J . Spectrum and frequency of genetic variants in sporadic amyotrophic lateral sclerosis. Brain Commun. 2023; 5(3):fcad152. PMC: 10202555. DOI: 10.1093/braincomms/fcad152. View

Byrne S, Walsh C, Lynch C, Bede P, Elamin M, Kenna K . Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2010; 82(6):623-7. DOI: 10.1136/jnnp.2010.224501. View

Ludolph A, Drory V, Hardiman O, Nakano I, Ravits J, Robberecht W . A revision of the El Escorial criteria - 2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015; 16(5-6):291-2. DOI: 10.3109/21678421.2015.1049183. View

Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen P . Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019; 20(7-8):538-548. PMC: 6768722. DOI: 10.1080/21678421.2019.1646769. View

Dorst J, Chen L, Rosenbohm A, Dreyhaupt J, Hubers A, Schuster J . Prognostic factors in ALS: a comparison between Germany and China. J Neurol. 2019; 266(6):1516-1525. DOI: 10.1007/s00415-019-09290-4. View

Marin B, Boumediene F, Logroscino G, Couratier P, Babron M, Leutenegger A . Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol. 2016; 46(1):57-74. PMC: 5407171. DOI: 10.1093/ije/dyw061. View

Wiesenfarth M, Gunther K, Muller K, Witzel S, Weiland U, Mayer K . Clinical and genetic features of amyotrophic lateral sclerosis patients with mutations. Brain Commun. 2023; 5(2):fcad087. PMC: 10065188. DOI: 10.1093/braincomms/fcad087. View

Hubers A, Just W, Rosenbohm A, Muller K, Marroquin N, Goebel I . De novo FUS mutations are the most frequent genetic cause in early-onset German ALS patients. Neurobiol Aging. 2015; 36(11):3117.e1-3117.e6. DOI: 10.1016/j.neurobiolaging.2015.08.005. View

10.

Agosta F, Al-Chalabi A, Filippi M, Hardiman O, Kaji R, Meininger V . The El Escorial criteria: strengths and weaknesses. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 16(1-2):1-7. DOI: 10.3109/21678421.2014.964258. View

11.

Reilich P, Schoberl F, Hiebeler M, Tonon M, Ludolph A, Senel M . Myelitis as a side effect of tofersen therapy in SOD1-associated ALS. J Neurol. 2023; 271(4):2114-2118. PMC: 10973064. DOI: 10.1007/s00415-023-12130-1. View

12.

Daria T, Muller K, Oidovdorj G, Baatar K, Boldbaatar P, Sarangerel J . Genotypes of amyotrophic lateral sclerosis in Mongolia. J Neurol Neurosurg Psychiatry. 2019; 90(11):1300-1302. DOI: 10.1136/jnnp-2019-320640. View

13.

Rosenbohm A, Peter R, Erhardt S, Lule D, Rothenbacher D, Ludolph A . Epidemiology of amyotrophic lateral sclerosis in Southern Germany. J Neurol. 2017; 264(4):749-757. DOI: 10.1007/s00415-017-8413-3. View

14.

Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen P . Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2015; 87(1):12-20. DOI: 10.1136/jnnp-2015-311387. View

15.

Hannaford A, Pavey N, van den Bos M, Geevasinga N, Menon P, Shefner J . Diagnostic Utility of Gold Coast Criteria in Amyotrophic Lateral Sclerosis. Ann Neurol. 2021; 89(5):979-986. DOI: 10.1002/ana.26045. View

16.

Brettschneider J, Del Tredici K, Toledo J, Robinson J, Irwin D, Grossman M . Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013; 74(1):20-38. PMC: 3785076. DOI: 10.1002/ana.23937. View

17.

Brown C, Lally C, Kupelian V, Flanders W . Estimated Prevalence and Incidence of Amyotrophic Lateral Sclerosis and SOD1 and C9orf72 Genetic Variants. Neuroepidemiology. 2021; 55(5):342-353. DOI: 10.1159/000516752. View

18.

Hamdi N, Mueller K, Hamza A, Soliman R, Onbool E, Omran K . First insights into genotype and phenotype of familial amyotrophic lateral sclerosis in Egypt: early onset and high consanguinity. Front Med. 2024; 18(6):1115-1118. DOI: 10.1007/s11684-024-1100-8. View

19.

Rosenbohm A, Liu M, Nagel G, Peter R, Cui B, Li X . Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany. J Neurol. 2018; 265(4):774-782. DOI: 10.1007/s00415-018-8735-9. View

20.

Wiesenfarth M, Dorst J, Brenner D, Elmas Z, Parlak O, Uzelac Z . Effects of tofersen treatment in patients with -ALS in a "real-world" setting - a 12-month multicenter cohort study from the German early access program. EClinicalMedicine. 2024; 69:102495. PMC: 10878861. DOI: 10.1016/j.eclinm.2024.102495. View